WHO Reviews Ervebo Vaccine Options for Bundibugyo Outbreak in Congo and Uganda
The World Health Organization is reviewing whether the licensed Ebola vaccine Ervebo could provide cross-protection during an outbreak of Bundibugyo virus disease in the Democratic Republic of the Congo and Uganda, after the outbreak was treated as a 2026 Public Health Emergency of International Concern.
In emergency guidance dated May 28, 2026, WHO assessed the possible use of Ervebo while health authorities consider vaccine options for a disease caused by Orthoebolavirus bundibugyoense. The guidance does not establish that Ervebo provides clinically proven protection against Bundibugyo virus disease.
The decision places vaccine evaluation alongside the broader international response to an outbreak involving two countries. It also highlights a central challenge: health authorities are considering whether an existing product could help before a vaccine designed specifically for Bundibugyo virus is available.
What WHO is reviewing
WHO’s Technical Advisory Group on Candidate Vaccine Prioritization met on May 19 and May 25 to review the epidemiological situation and candidate vaccines for Bundibugyo virus disease. The group also examined options for evaluating those vaccines in outbreak settings.
The advisory work is not the same as authorizing a new vaccine or declaring Ervebo an approved Bundibugyo vaccine. Instead, it is part of an assessment of what products and study approaches could be used during an emergency involving a virus related to, but distinct from, the viruses that cause Ebola disease.
WHO’s emergency guidance addresses the possibility that Ervebo might provide some cross-protection. The agency’s position is an assessment for outbreak use, not a finding that the vaccine has been demonstrated to prevent Bundibugyo virus disease in clinical practice.
Control measures remain central
WHO says vaccination research cannot replace the basic public-health measures needed to contain the outbreak. Its guidance stresses continued surveillance, contact tracing, clinical management, infection prevention and community engagement.
Those measures are important because vaccine decisions may require further evaluation while health authorities are already responding to suspected transmission. Surveillance helps identify cases and chains of spread. Contact tracing can locate people exposed to an infected person, while clinical care and infection-prevention practices reduce risks for patients, health workers and communities.
Community engagement is also part of the response. WHO includes it with the other control measures rather than treating vaccination as a stand-alone solution.
Next steps for vaccine development
WHO is calling for accelerated development and evaluation of vaccines specifically designed for Bundibugyo virus disease, as well as vaccines intended to provide broader protection against filoviruses.
The agency’s documents do not announce authorization or deployment of a Bundibugyo-specific vaccine. They instead describe an effort to prioritize candidates and determine how they might be evaluated during outbreaks.
The immediate practical question is therefore whether Ervebo can play a role while that work continues. WHO’s guidance provides a framework for considering the option, but it does not remove the need for evidence about protection against the virus responsible for the current outbreak.
WHO’s technical report identifies the Democratic Republic of the Congo and Uganda as the affected countries and places the response within the 2026 international emergency. The agency has not established clinically proven protection from Ervebo against Bundibugyo virus disease, making continued outbreak surveillance and other control measures essential as vaccine assessments proceed.
Sources
- WHO Technical Advisory Group on Candidate Vaccine Prioritization: meeting report, World Health Organization
- WHO emergency guidance on use of licensed Ebola vaccine during Bundibugyo virus disease outbreaks, World Health Organization
- Ebola vaccines: questions and answers, World Health Organization
Look for updates to this story
Discover more from Interactive News
Subscribe to get the latest posts sent to your email.
